We assessed the concentration of nitroglycerin (GTN) measured in plasma at different sampling sites in the circulation during a constant i.v. infusion. Twenty patients with chronic congestive cardiac failure underwent hemodynamic monitoring during i.v. GTN infusion. Our end point was a reduction in pulmonary capillary wedge pressure by at least 25 % of its control value or a 10-fold increment over the initial infusion rate. Nitroglycerin infusion produced no change in heart rate, a reduction in mean arterial pressure from 90 21 (+ SD) to 83 + 17 mm Hg (p< 0.001), a fall in total peripheral resistance from 24.3 ± 10.8 to 20.8 7.0 units (p < 0.02), and a substantial reduction in both pulmonary capillary wedge pressure (from 27 6 to 20 ± 6 mm Hg, p < 0.001) and right atrial pressure (from 12 ± 4 to 8 ± 4 mm Hg, p < 0.001). The concentrations of GTN in the pulmonary artery and systemic artery were similar (29.8 ng/ml ± 52.8 and 25.1 ± 48.4 ng/ml, respectively) and considerably higher than the concentration in the peripheral vein (7.3 ± 15.4 ng/ml). There was a 17.4 ± 19.1% extraction of GTN across the pulmonary vascular bed and a 60.8 ± 27.2% extraction across the arterial-venous bed (p < 0.001). There was no relationship between the arterial-venous extraction and the magnitude of arterial plasma GTN concentration, the duration of the infusion of GTN or the total dose administered. These data show that a better understanding of GTN pharmacokinetics is provided by simultaneous arterial and venous samples.
THE EXPANDING clinical role for nitroglycerin has led to an increase in the frequency of i.v. administration of this drug in hospitalized patients with cardiovascular disease. We previously investigated the pharmacokinetics of i.v. nitroglycerin in patients with congestive cardiac failure and examined the relationship between its arterial concentration and hemodynamic effects. ' These studies showed a good relationship between the infusion rate of nitroglycerin and its arterial concentration. However, Wei and Reid2 found no correlation between the infusion rate of nitroglycerin and its venous concentration in a study of four patients. In a preliminary report, Brymer and co-work-ers3 found different concentrations of nitroglycerin in simultaneous samples drawn from the superior vena cava, the brachial artery and a peripheral vein in four patients who had received sublingual nitroglycerin. ' We speculated that the lack of agreement between our results and others might be related to a circulatory gradient for nitroglycerin.
The objective of the current study was to assess the influence of the sampling site on plasma nitroglycerin concentration during a constant i.v. infusion.
Materials and Methods Patients
Twenty patients with congestive heart failure formed the study group. There were 13 males and seven females, mean age 61 years (range 43-84 years). In 11 patients, heart failure was a complicating feature of acute myocardial infarction within the previous 48 hours; in the nine other patients, heart failure had been established for at least 3 months and was secondary to atherosclerotic heart disease in eight and cardiomyopathy in one. All patients with chronic congestive failure were resistant to conventional medical management, including optimal digitalization and the use of loop diuretics. Four patients had previously received long-acting nitrate therapy, which was discontinued at least 24 hours before the commencement of the study.
After the patients gave informed consent, hemodynamic monitoring was undertaken in a standardized fashion. A Swan-Ganz thermodilution catheter was placed in the pulmonary artery and a Teflon cannula in the radial artery. Right atrial (RAP), pulmonary arterial (PAP) and systemic arterial pressures were monitored, and pulmonary capillary wedge pressure (PCWP) was obtained by balloon occlusion. Cardiac output (CO) was measured at least in duplicate by the thermodilution technique with injection of 10 ml of ice-cold 5% dextrose in water into the right atrium.4 After a control period of 30 minutes, during which hemodynamic measurements were shown to be reproducible, i.v. GTN was infused at an initial rate of 15-20 ,ug/min into a peripheral vein of the arm that did not contain the radial cannula and Swan-Ganz catheter. Our aim was to reduce PCWP by at least 25% of its control value; the infusion rate was increased in a stepwise fashion (50% increments of previous rate) every 10-15 minutes until the desired hemodynamic end point was achieved or a greater than 10-fold increment of the initial infusion rate had been attained, hereafter defined as the peak rate. Hemodynamic monitoring was performed during the infusion and complete measurements, including CO, were obtained at the peak rate. The infusion was maintained at the peak rate for at least 15 minutes because experience has shown that a hemodynamic steady state is achieved at this time.' The infusion was then stopped and monitoring continued for 15-30 minutes until hemodyamic measurements returned to control levels.
Stroke index was calculated as CI/HR and total peripheral resistance as (MAP -RAP)/CO, where CI = 1273 VOL 66, No 6, DECEMBER 1982 cardiac index, HR heart rate, MAP = mean arterial pressure and RAP right atrial pressure. Arterial blood samples for GTN determination were withdrawn from the radial cannula during the control period and at the peak rate. At peak infusion rate, simultaneous samples were withdrawn from the pulmonary artery port of the Swan-Ganz catheter and from the peripheral vein of the arm contralateral to the arm in which GTN was infused. Blood samples were withdrawn into glass syringes and immediately centrifuged at 5°C; the decanted plasma was frozen at -20°C. Subsequent analysis was performed using a gas-liquid chromatograph with dinitrobenzene as the internal standard, according to a modification of a method previously described.5 This method involves a double hexane extraction, drying on ice under a stream of nitrogen gas and reconstitution in 100 ,l of benzene. The method has a lower limit of sensitivity of 0.3 ng/ml, and our recovery of nitroglycerin at this level is 82.8 + 10.5% (n = 5). The coefficient of variation is 12% at 0.3 ng/ml (n 5), 7% at 5 ng/ml (n = 4), and 5% at 10 ng/ml (n = 5).
Pharmacokinetic variables were calculated using the formulas infusion rate ss clearance clearance x t½/2 Vd 0.693 where C steady-state concentration, Vd volume of distribution and t½2 = half-life.6 Arterial-venous extraction was calculated using plasma GTN concentration and the formula arterialvenous x 100%. arterial Arterial plasma samples for GTN were withdrawn at 0.5, 1, 2, 5 and 10 minutes after cessation of i.v. GTN. The t1/2 for GTN disappearance was calculated from a semilog plot of plasma GTN concentration against time after cessation of infusion. In subjects 3, 4 and 12, the arterial GTN concentration was undetectable before enough data could be obtained -for the t/2 determination.
GTN was prepared for i.v. use as a 0.5% solution in ethanol. A 9.5% lactose mixture (Parke-Davis) (6.3 g) was added to ethyl alcohol (99%) to a total volume of 120 ml. The alcoholic supematant was decanted and passed through a 0.22-,u Millipore filter. The solution was assayed using our gas-liquid chromatograph method. Immediately before use, the GTN solution was added to 5% dextrose in water (in glass bottles) to produce a concentration of 100 jug/ml. The solution was delivered from 50-ml glass syringes through Teflon tubing by Harvard pump. We have shown by direct assay of delivered solution that no loss of GTN occurs over the infusion rates used in this study (unpublished observations).
The data were analyzed by t test (paired observations), linear regression analysis and analysis of variance (ANOVA) where appropriate.
Results
GTN infusion in our patients produced no change in heart rate from its control value of 89 + 18 beats/min ( + SD) and a decrease in mean arterial pressure from 90 ± 21 to 83 ± 17 mm Hg (p < 0.001). Total peripheral resistance decreased from 24.3 ± 10.8 to 20.8 ± 7 units (p < 0.02), and both pulmonary capillary wedge pressure (27 ± 6 to 20 ± 6 mm Hg, p < 0.001) and right atrial pressure (12 ± 4 to 8 ± 4 mm Hg, p < 0.001) decreased substantially. Accompanying these pressure changes there were slight increases in cardiac index (2.0 ± 0.5 to 2.2 ± 0.5 I/min/m2, p < 0.001) and stroke index (22.8 ± 7.9 ml/beats/m2 to 25.1 ± 6.9 ml/beats/m2, p < 0.05). The control hemodynamic observations confirmed the presence of important left ventricular dysfunction in our patients.
A wide range of GTN infusion rates was required to achieve the objectives of this study (table 1) . Furthermore, despite similar infusion rates, there was considerable variation in plasma GTN concentration. Subject 19 had low GTN concentrations despite a high infusion rate, which suggests that drug delivery may have been impaired in this instance. However, analysis of the relationship between infusion rate of GTN and plasma concentration showed a good overall agreement; r = 0.84, 0.8 1 and 0.74 for pulmonary arterial, venous and arterial concentrations, respectively (p < 0.001, ANOVA).
The concentrations of GTN achieved in the pulmonary artery and the systemic artery were similar (29.8 52.8 and 25.1 + 48.4 ng/ml, respectively) and considerably higher than that in the peripheral vein (7.3 14.3 ng/ml) (table 1). Because there was a large variation in the peak infusion rate and the resultant plasma GTN concentration, we converted the data to percentages to more efficiently analyze GTN concentration at the various sampling sites within each patient. The pulmonary artery concentration was arbitrarily assigned a value of 100%, and the arterial and venous concentrations were expressed as a percentage of the concentration in the pulmonary artery. This revealed a marked difference between the radial artery (83 19%) and the peripheral vein (36 30%) (p < 0.001, ANOVA). GTN disappearance across vascular beds was assessed by analysis of extraction of GTN across the pulmonary bed and arterial-venous bed. Percent extraction in these two regions was 17.4 ± 19. 1% and 60. 8 27.2%, respectively (p < 0.001, ANOVA). We questioned whether the magnitude of the arterial plasma concentration, the duration of the GTN infusion (265 ± 9 minutes), or the total dose administered (13.0 ± 16.8 mg) influenced the arterialvenous extraction. Regression analysis of these variables against arterial concentration showed no relationship (r = 0.22, 0. 10,and 0. 15, respectively).
Also displayed in table 1 is the t½ of GTN derived from arterial samples after cessation of i.v. infusion of GTN. The t/2 of 1.4 ± 0.8 minutes is similar to the value of 1.9 minutes we reported previously.' Arterial and venous clearance and volume of distribution calculations are shown in table 2. For purposes of the venous volume of distribution calculation, venous and arterial t½/2 values were assumed to be the same. This assumption was necessary because tl/2 data were derived only from arterial samples. Canine studies of the pharmacokinetics of GTN in our laboratory suggest that the venous t/2 is slightly greater than the arterial t'/2. Therefore, the assumption used in the calculations probably gives rise to an underestimate of true venous volume of distribution.' The clearance and volume of distribution determined from arterial concentrations were significantly smaller than those determined using venous concentrations (p < 0.001 and 0.01, respectively, paired t test).
Discussion
This study demonstrates that a circulatory gradient for GTN exists in man during constant i.v. infusion of the drug. This gradient was small between the pulmonary artery and systemic artery, but substantial between the systemic artery and peripheral vein. The gradient was observed when a hemodynamic steady state had been achieved and when the infusion rate had been maintained for at least five elimination half lives of the drug. Moreover, this gradient persisted at all infusion rates and was independent of both the duration of infusion and magnitude of the plasma concentration. Thus, the gradient was not saturable under the conditions of this study.
The mechanism for this gradient is unclear, but could relate to several factors. Uptake of GTN by blood vessels or binding to vascular receptors could contribute to the arterial-venous extraction of GTN. Evidence for this comes from the work of Fung and Kamiyaj8 who infused GTN into the vena cava of rats and demonstrated regional differences in GTN uptake; vascular uptake was more avid in the vena cava than in the aorta. They further demonstrated that concentrations of GTN in rat blood vessels were 10-fold higher than in the plasma. Krantz et al.9 demonstrated loss of GTN during perfusion of rabbit coronary arteries in a Langendorf preparation.
We noted that the blood from the pulmonary artery had the highest concentration for GTN after systemic i.v. infusion and that there was considerably less extraction from pulmonary to peripheral artery than from peripheral artery to vein. The reasons for these findings are unclear, but could relate to a greater vascular uptake of GTN in the venous circulation as reported by Fung and Kamiya.8 If receptors were involved in this 1275 process of GTN uptake, a difference in receptor populations in peripheral arteries and veins could be operative. Preferential uptake of GTN by veins might explain the greater sensitivity to GTN in veins than in arteries; this has been observed in both clinical and experimental studies.'0 1I We recently confirmed the presence of an arterialvenous gradient during intravenous GTN infusion in the dog. 7 We found that after administration of GTN for 5 days, the blood pressure-lowering effect of GTN during a repeat i.v. infusion was attenuated and the arterial-venous gradient for GTN was eliminated. The disappearance of this gradient reflected a rise in the venous concentration possibly due to saturation at sites of GTN uptake. Whether such findings can be correlated with hemodynamic tolerance in man remains to be demonstrated.
Classic pharmacokinetic analysis is based on samples obtained from the systemic venous circulation and the assumption that the drug measured is equally distributed throughout the intravascular compartment. Our studies show that this assumption is invalid when applied to GTN. Consequently, a better understanding of the pharmacokinetics of this drug can be achieved when arterial and venous samples are used.
Information regarding simultaneous arterial and venous concentrations in man is limited to only a few other drugs. Patel and co-workers'2 suggested that soon after bolus adminstration of lidocaine, an arterialvenous gradient is demonstrable, "presumably secondary to the distribution phase of the drug,' but that this gradient disappears after steady state is established. Wilkinson and Rheingold'3 measured the arterial and venous blood alcohol concentrations after constantrate ethanol infusions in the dog. They observed a higher concentration in arterial than venous blood during infusion but a reversal of this relationship after cessation of the infusion. Kreye and Reske'4 demonstrated that there was an arterial-venous gradient for nitroprusside across the hind limb of the anesthetized rat, but not across its pulmonary vascular bed. 14 They suggested that the arterial-venous gradient in the hind limb reflected rapid in vivo inactivation of nitroprusside.
The observation that the vasoactive drugs, alcohol, nitroprusside, and nitroglycerin all have arterial-venous gradients raises the possibility that this finding may relate to the site and mechanism of action of these drugs. If such a relationship exists, the pharmacodynamic effects of a drug should be related more closely to the arterial than to the venous concentration. The physiologic effects of alcohol are more closely related to the arterial than to the venous concentration in man. '3 The demonstration of an arterial-venous gradient for a drug such as nitroglycerin has importance in pharmacokinetic determinations. The difference in the arterial and venous concentrations suggests that in addition to other sites of clearance such as the liver, the peripheral circulation is a major region for nitroglycerin distribution and clearance. Whether a similar gradient is shared by other vasoactive drugs, or indeed by other drugs in general is unknown. What insight arterial-venous concentration gradients provide into the mechanism of action of vasoactive drugs and the question of tolerance formation await further exploration.
